Naive antibody library derived monoclonal antibody against VP35 of Ebola virus

Ebola virus is notorious for causing severe and even deadly haemorrhagic fever in infected humans and nonhuman primates. The high fatality rate of Ebola virus disease (EVD) has highlighted the need for effective diagnosis and treatment. Two monoclonal antibodies (mAbs) have been approved by USFDA for treatment of EVD. Virus surface glycoprotein is the common target for diagnostic and therapy including vaccines. Even so, VP35, a viral RNA polymerase cofactor and interferon inhibitor could be a potential target to curb EVD. The present work describes the isolation of three mAb clones from a phage-displayed human naive scFv library against recombinant VP35. The clones showed binding against rVP35 in vitro and inhibition of VP35 in luciferase reporter gene assay. Structural modelling analysis was also carried out to identify the binding interactions involved in the antibody-antigen interaction model. This allows some insight into the fitness of the binding pocket between the paratope and target epitope which would be useful for the design of new mAbs through in silico means in the future. In conclusion, the information obtained from the 3 isolated mAbs could be potentially useful in the quest to improve VP35 targeting for therapeutic development in the future.

Automated summary

Ebola virus is notorious for causing severe and deadly haemorrhagic fever. Effective diagnosis and treatment are needed due to the high fatality rate. Two monoclonal antibodies have been approved for EVD treatment. The viral surface glycoprotein is a common target, but VP35 could be a potential target as well.